Pendulum
Pendulum Metabolic Daily Pro (30 Capsules) | Metabolism & Gut Health Probiotic | EMIS+
Pendulum Metabolic Daily Pro (30 Capsules) | Metabolism & Gut Health Probiotic | EMIS+
无法加载取货服务可用情况
Product Overview
Metabolic Daily Pro is the practitioner channel formulation of Pendulum Therapeutics' multi-strain probiotic platform, targeted at adults seeking adjunctive nutritional support for metabolic health. The formulation is a proprietary "next-generation" probiotic, distinguished from conventional Lactobacillus/Bifidobacterium products by the inclusion of strict-anaerobe colonic species — most notably Akkermansia muciniphila — that have historically been difficult to manufacture and stabilise in oral dosage form.
The five strains were selected for their complementary mechanisms in the gut: Akkermansia muciniphila supports mucin layer turnover and intestinal-barrier integrity; Clostridium butyricum and Anaerobutyricum hallii produce butyrate, the principal SCFA energy substrate of colonocytes; Clostridium beijerinckii contributes to acetate/butyrate production; and Bifidobacterium infantis supports infant-type bifidobacterial cross-feeding. Capsules are delivered in an acid-resistant shell to protect viability through gastric transit. The product is intended to be used as part of a balanced diet and is not a substitute for prescribed glucose-lowering therapy.
Specifications
| Manufacturer | Pendulum Therapeutics, Inc. (United States) |
|---|---|
| Product | Metabolic Daily Pro — multi-strain probiotic capsule (practitioner channel) |
| Pack size | 30 capsules per bottle (one-month supply at 1 capsule/day) |
| Active strains | Akkermansia muciniphila WB-STR-0001; Clostridium butyricum; Clostridium beijerinckii; Anaerobutyricum hallii; Bifidobacterium infantis |
| Mechanism class | Mucin-degrading and butyrate-producing consortium; SCFA and gut-barrier supportive |
| Dosage form | Acid-resistant capsule (gastric-protective shell) |
| Dietary attributes | Vegan capsule shell; gluten-free; non-GMO; soy-free; dairy-free |
| Storage | Refrigerate at 2–8°C to preserve viable cell count; protect from heat and humidity |
| Manufacturing standards | Manufactured under cGMP (US FDA 21 CFR Part 111 dietary supplement regulations); supplier facilities operate to NSF/IFS food-safety standards |
| Regulatory positioning | Marketed as a medical probiotic dietary supplement in the United States. In Singapore, classified by HSA as a health supplement under the Health Products Act and not as a registered therapeutic product or medical device. Not intended to diagnose, treat, cure, or prevent any disease. |
| Key clinical evidence | Perraudeau et al., BMJ Open Diabetes Research & Care 2020 — 12-week, randomised, double-blind, placebo-controlled trial; HbA1c −0.6 percentage points and post-prandial glucose AUC −33% versus placebo in adults with type 2 diabetes. |
Key Applications
- Adjunctive nutritional support of glycaemic and post-prandial glucose response in adults with diet-controlled or metformin-managed type 2 diabetes (under clinician supervision).
- Microbiome support in adults with metabolic syndrome features — central adiposity, dyslipidaemia, prediabetes — as part of a structured lifestyle programme.
- Restoration of mucin-degrading and butyrate-producing bacterial niches following broad-spectrum antibiotic exposure.
- Adjunctive support after weight-loss interventions (caloric restriction, GLP-1 receptor agonist therapy, bariatric surgery) where intestinal barrier and SCFA function are clinically relevant.
- Practitioner-led functional and integrative medicine programmes addressing gut-barrier dysfunction.
Frequently Asked Questions
What clinical evidence supports the formulation?
The five-strain Pendulum platform was evaluated in a 12-week, multi-site, double-blind, randomised, placebo-controlled clinical trial in adults with type 2 diabetes (Perraudeau et al., 2020, BMJ Open Diabetes Research & Care). The active arm achieved a statistically significant reduction in HbA1c of approximately 0.6 percentage points and a 33% reduction in post-prandial glucose AUC versus placebo on background standard care.
How does this differ from conventional probiotics?
Standard probiotics are dominated by Lactobacillus and Bifidobacterium strains, which colonise the small intestine. Metabolic Daily Pro contains strict colonic anaerobes — including Akkermansia muciniphila — whose mucin-degradation and butyrate-production pathways are mechanistically tied to gut-barrier integrity and metabolic homeostasis rather than simple lactic-acid fermentation.
Why does the product require refrigeration?
Strict anaerobes such as Akkermansia muciniphila are sensitive to oxygen, heat and humidity. Refrigeration at 2–8°C and acid-resistant encapsulation preserve viable colony-forming units (CFU) over the labelled shelf life. Storage at room temperature for short periods during transit is acceptable per the manufacturer's stability data.
Is it safe with metformin or other glucose-lowering therapy?
The Pendulum trial enrolled patients on stable metformin and standard care. As with any dietary supplement that may influence glycaemic response, patients on insulin, sulphonylureas or GLP-1 receptor agonists should be reviewed by their treating clinician for hypoglycaemia risk and dose-titration considerations. The product is not a substitute for prescribed therapy.
What is the regulatory status in Singapore?
In Singapore the product is supplied as a health supplement under the Health Products Act and is not registered as a therapeutic product or medical device with the Health Sciences Authority (HSA). The manufacturer operates under US FDA 21 CFR Part 111 cGMP requirements for dietary supplements. Essential Medical International Supplies Pte Ltd (emis.asia) is the authorised reseller and recommends use under qualified healthcare-professional guidance.
分享
